TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19347979
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral carboxyaminoimidazole
Study: 21425620
Drug: Low power
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low power laser (LPL) treatment, frequency of 73 Hz, 10 minutes per treatment, total dose 15 J.
Study: 30600526
Drug: IV-only multimodal
Normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-only multimodal analgesics (control group)
Study: 3071032
Drug: diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 50 mg plus B vitamins (B1, B6, B12)
Study: 31515667
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg abiraterone acetate taken with a continental breakfast (CB)
Study: 21389855
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (40 mg)
Study: 19794266
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once daily for 1 week, amoxicillin 1g b.i.d, omeprazole 20 mg b.i.d, bismuth 240 mg b.i.d for 2 weeks (AAO-B group)
Study: 15906123
Drug: Alvimopan 6
Normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alvimopan 6 mg
Study: 8423882
Drug: Botulinum-A toxin
Normalized name: Botulinum A neurotoxin
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum-A toxin (BTX-A) injections
Study: 10989320
Drug: 17-beta estradiol
Normalized name: 17-beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-beta estradiol (E) infusion (20 ng/min)
Study: 10692926
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous infusion of midazolam (0.2 mg/ml of normal saline at a rate of 1 mg/h)
Study: 15849749
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and 800 ml free broad spectrum sunscreens with SPF 25 provided yearly
Study: 12351466
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein 30 g/day, isoflavones 132 mg/day
Study: 23548250
Drug: Guided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-delivered acceptance and commitment therapy (ACT)
Study: 26420261
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GA and IS samples
Study: 23621675
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and ibuprofen
Study: 23621675
Drug: Extended-release diclofenac
Normalized name: diclofenac Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release diclofenac
Study: 9003265
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin
Study: 21712706
Drug: Nonfractionated (NF)
Normalized name: NFS-02
DrugBank: NFS-02 (DB18422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfractionated (NF) dose group: paclitaxel (200 mg/m(2)) and carboplatin (AUC=6) on day 1
Study: 21527231
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received treatment for constipation and recurrent urinary tract infections (UTIs)
Study: 18384519
Drug: 24-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week treatment regimen of peginterferon and ribavirin
Study: 10896845
Drug: Free nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Free nicotine patches plus proactive telephone peer support
Study: 10896845
Drug: Free nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Free nicotine patches only
Study: 7609499
Drug: sublingual lacidipine
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual lacidipine 4 mg
Study: 8314271
Drug: sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual nifedipine 10 mg
Study: 3280158
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Diltiazem and Nifedipine)
Study: 2899588
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg and piperacillin 4 g (3 doses)
Study: 25332468
Drug: Control essential
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control essential amino acids (1.85 g of Leu)
Study: 30833368
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy
Study: 12109823
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy plus radiotherapy
Study: 29901296
Drug: -blocker Fokusin
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -blocker Fokusin 0.4 mg once a day
Study: 10518081
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (4 IU/m(2)/d, 6 IU/m(2)/d, 8 IU/m(2)/d)
Study: 19776136
Drug: Cocoa powder
Normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa powder with 500 mL skim milk/d (C+M)
Study: 17305650
Drug: Both aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both aspirin and antioxidant vitamins
Study: 10912607
Drug: Intensive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive physical therapy
Study: 28164396
Drug: 5α-reductase inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5α-reductase inhibitors (5-ARIs)
Study: 31879231
Drug: Endovenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous treatment with lysis and stenting
Study: 17391164
Drug: Topiramate 96
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 96 mg/day
Study: 17391164
Drug: Topiramate 192
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 192 mg/day
Study: 19451404
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg single dose
Study: 9422303
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia with mepivacaine 20 mg/ml and epinephrine 5 microg/ml, 15‐20 ml (Group E)
Study: 1747644
Drug: Bismuth subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subcitrate 120 mg four times a day for four weeks, metronidazole 400 mg three times a day for one week, plus amoxycillin 500 mg three times a day for the first week
Study: 26864127
Drug: D2-biofortified bread
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2-biofortified bread (25 µg D2/d)
Study: 15098799
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (240 ml, regular-strength)
Study: 17662090
Drug: L-Citrulline
Normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Citrulline
Study: 3319859
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin treatment (CI)
Study: 2873010
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg flunitrazepam
Study: 11717622
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without beta(2)-adrenergic receptor agonists (group B)
Study: 9137794
Drug: Standard-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose cytarabine (SDAC: 100 mg/sqm 24 hours infusion over seven days)
Study: 11977509
Drug: Shu Feng
Normalized name: Feng Mi
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shu Feng Huo Luo Pian, 2 pills, p.o., bid, supplemented with calcium Caltrate D 0.6 g, p.o., qd for 2 courses (2 weeks each)
Study: 22874843
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium load
Study: 3931136
Drug: methylclonazepam 1
Normalized name: N-Methyllorazepam
DrugBank: Lormetazepam (DB13872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylclonazepam 1 mg
Study: 17110897
Drug: Continuous intraperitoneal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraperitoneal insulin infusion (CIpii)
Study: 29231544
Drug: Oral lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral lactulose (3 times a day for 8 weeks)
Study: 23355041
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of gemcitabine and S‐1 (gemcitabine 1,000 mg/m(2) on days 1 and 15 and S‐1 40 mg/m(2) b.i.d. on days 1‐14, repeated every 4 weeks)
Study: 7076116
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CDCA and UDCA
Study: 7076116
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg per kg per day of ursodeoxycholic acid (UDCA)
Study: 28325124
Drug: Obstetric gel
Normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstetric gel
Study: 9048267
Drug: Converting enzyme
Normalized name: Prohormone converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting enzyme inhibitors
Study: 23507709
Drug: Low-dose rosuvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rosuvastatin (2.5 mg/day)
Study: 3181102
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 60 mg
Study: 10480041
Drug: Guided self-hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-hypnotic relaxation
Study: 1461786
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (40 mg/Kg/dose for 4 days)
Study: 1461786
Drug: Intravenous amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amoxicillin (40 mg/Kg/dose for 4 days)
Study: 10973651
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (goserelin, 3.6 mg every 4 weeks) plus oral placebo
Study: 10973651
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (goserelin, 3.6 mg every 4 weeks) plus oral continuous combined estradiol-norethisterone acetate add-back therapy daily for 24 weeks
Study: 21319897
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) intervention, 8-week group during pregnancy and 3 individual booster sessions postpartum
Study: 25912697
Drug: Serelaxin 10
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin 10 µg·kg(‐1)·day(‐1)
Study: 17962502
Drug: 12-minute visit
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-minute visit from a volunteer with a therapy dog
Study: 19343272
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once-weekly
Study: 2007377
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg aspirin daily (group 1)
Study: 28524257
Drug: 30-week oral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30-week oral language intervention programme
Study: 19303145
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire (SAQ)
Study: 8432223
Drug: Acarbose 25
Normalized name: acarbose 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 25 mg powdered, 3 times a day with meals
Study: 9084544
Drug: omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 40 mg
Study: 8836705
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg
Study: 8644481
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg
Study: 19590458
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh (128 mg)
Study: 24231627
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus pemetrexed (400 mg/m2 at first dose and 250 mg/m2 weekly thereafter)
Study: 31768718
Drug: Multidisciplinary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidisciplinary intervention for encopresis (MIE); Treatment for constipation, 10-day behavioral intervention utilizing suppositories
Study: 10371003
Drug: Follow-up questionnaire
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up questionnaire (1-4 years after treatment)
Study: 12614088
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and mineral supplement among diabetic participants
Study: 30641815
Drug: Full ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full ozone therapy
Study: 1607582
Drug: Study drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drugs (encainide, flecainide or moricizine)
Study: 11224578
Drug: High fluoride
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluoride ingestion (2.4, 4.6, 5.6, and 13.5 mg/l)
Study: 16856904
Drug: Metronidazole plus
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole plus amoxicillin (M+A) for 7 days
Study: 28633702
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT)
Study: 21087166
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (50-μg) plus oxytocin
Study: 18155284
Drug: Grass allergen
Normalized name: orchardgrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergen tablet immunotherapy (GRAZAX)
Study: 20122374
Drug: Videoteleconferencing anger
Normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Videoteleconferencing anger management therapy (n = 61)
Study: 20122374
Drug: In-person anger
Normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In-person anger management therapy (n = 64)
Study: 8855675
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg once daily
Study: 6089857
Drug: edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium 1 mg kg‐1
Study: 8452166
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for 7-14 days
Study: 18594417
Drug: Enoxaparin administration
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin administration
Study: 10999778
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg calcium daily
Study: 3048225
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg scopolamine hydrobromide
Study: 3899624
Drug: Flunarizine at
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine at doses of 15-20 mg daily
Study: 25991692
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate 500 mg, three times daily for 12 weeks
Study: 25201463
Drug: Mg + H2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg + H2 group
Study: 20598044
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (cetrorelix)
Study: 1943183
Drug: Stanford solution
Normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanford solution
Study: 27037996
Drug: 70 mL
Normalized name: ALCOHOL 70 mL TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mL of concentrated nitrate-rich beetroot juice (BR)
Study: 24897504
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no paracetamol)
Study: 30539492
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment (LRT)
Study: 20697801
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) with docetaxel, doxorubicin and cyclophosphamide (TAC)
Study: 24833235
Drug: Rivaroxaban vs
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban vs Warfarin (no AAD)
Study: 1897307
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg Pasteur BCG by intradermal injection
Study: 25596270
Drug: Subcutaneous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous bortezomib
Study: 31707149
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 325 mg
Study: 15508780
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment
Study: 20454891
Drug: High-dose B-complex
Normalized name: vitamin B complex
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose B-complex vitamin and mineral supplement (Berocca(R))
Study: 22707560
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (9 g/day; 1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)
Study: 8743406
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg naproxen
Study: 25566930
Drug: Edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 15 mg (on-dialysis)
Study: 17997115
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg salbutamol via pMDI+ Volumatic
Study: 17997115
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg salbutamol via pMDI+ Volumatic
Study: 29168741
Drug: Tyrosine 150
Normalized name: TYROSINE 150 ug / PANTOTHENIC ACID 15 mg / METHYLCOBALAMIN 1 mg / CHOLECALCIFEROL 1200 [USP'U] / THIAMINE 1 mg / LEVOMEFOLATE CALCIUM 6 mg / RIBOFLAVIN 5'-PHOSPHATE 3 mg / PYRIDOXAL 5-PHOSPHATE 10 mg / NIACINAMIDE 5 mg / ASCORBIC ACID 85 ug ORAL TABLET [Neuro 110]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine 150 mg/kg
Study: 12887139
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg/70 kg
Study: 19454870
Drug: Lacosamide 600
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide 600 mg/d
Study: 19454870
Drug: Lacosamide 400
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide 400 mg/d
Study: 3931661
Drug: Pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 1 mg kg‐1
Study: 788143
Drug: Meningococcal group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal group A polysaccharide vaccine
Study: 333906
Drug: Porcine intestinal
Normalized name: porcine intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine intestinal heparin (2 units/ml)
Study: 16083201
Drug: Sham traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham traction with routine conservative treatment
Study: 11491207
Drug: Pioglitazone HCl
Normalized name: PIOGLITAZONE HCL
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone HCl 30 mg once daily
Study: 23278328
Drug: Infusion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion group